Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105313 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
A Phase 1 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00105313 is a Phase 1 study that was terminated before completion, run by MedImmune. The registered enrollment target is 80 participants.
The verdict
NCT00105313, a Phase 1 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.
Interventions
- DRUG MEDI-507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105313
The ClinicalTrials.gov registry entry for NCT00105313 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI-507 is the first listed.
NCT00105313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00105313 about?
NCT00105313 is a clinical study titled "Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia". For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immu...
What is the current status of trial NCT00105313?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2005-02.
What interventions are being tested in trial NCT00105313?
The interventions under investigation include: MEDI-507 (DRUG).
Who is sponsoring clinical trial NCT00105313?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.